APTN — ADAPTIN BIO, INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1938571 ·
Last close
$6.27
Market Cap
—
52W High
—
52W Low
—
ADV30
100
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -1,144,153 | -1,146,096 | 706,117 | 301,309 | 2,481,688 |
| Sep 2025 | 0 | 0 | -1,675,612 | -1,675,612 | 979,474 | 579,089 | 1,860,552 |
| Jun 2025 | 0 | 0 | -1,520,855 | -1,520,855 | 1,662,635 | 1,351,519 | 1,188,226 |
| Mar 2025 | 0 | 0 | -850,458 | -603,084 | 2,854,004 | 2,374,229 | 1,108,740 |
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,414,943 | -5,167,569 | 619,159 | 2,108,555 | -1,489,396 | — |
| Dec 2024 | 0 | -155,374 | -161,160 | 12,619 | 286,676 | -274,057 | — |
| Dec 2023 | — | — | -85,593 | 380 | 113,277 | -112,897 | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-5,710,581
OpCashFlow TTM
—
Assets (Latest)
$706,117
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.29B | $414.87 | — |
| GILD | GILEAD SCIENCES, INC. | $187.44B | $151.17 | — |
| MRNA | Moderna, Inc. | $89.83B | $225.00 | — |
| ARGX | ARGENX SE | $51.31B | $825.03 | — |
| RVMD | Revolution Medicines, Inc. | $40.67B | $189.76 | — |
News headlines (Yahoo Finance, 1h cache)
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-09-18 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced
2026-09-14 12:35 · Yahoo
Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101
2026-08-20 20:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.